Actively Recruiting
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Led by Weill Medical College of Cornell University · Updated on 2025-08-15
15
Participants Needed
1
Research Sites
412 weeks
Total Duration
On this page
Sponsors
W
Weill Medical College of Cornell University
Lead Sponsor
E
Epizyme, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a clinical trial to evaluate the feasibility and safety of giving tazemetostat followed by standard of care CAR T cell infusion in previously treated diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The investigators hypothesis is that this combination has the potential to significantly improve the ability of CART cells to recognize and kill lymphoma cells without a significant impact on safety. Participants will receive the tazemetostat pills before and after receiving their CAR T cell therapy, for up to 12 months after CAR T cell administration. Patients will be followed for up to 5 years.
CONDITIONS
Official Title
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of diffuse large B-cell lymphoma, follicular lymphoma, or mantle cell lymphoma
- Eligible to receive standard of care CAR T cells
- Have received at least one prior therapy
You will not qualify if you...
- Active viral infection with HIV or hepatitis type B or C
- Active, uncontrolled systemic fungal, bacterial, or viral infection
- Currently receiving treatment for another cancer
- Pregnant or breastfeeding
- Unable to take oral medication
- Significant past medical history such as recent stroke, pulmonary embolism, myocardial infarction, congestive heart failure, uncontrolled hypertension, or certain arrhythmias
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Weill Cornell Medicine/NewYork-Presbyterian Hospital
New York, New York, United States, 10065
Actively Recruiting
Research Team
N
Nicole Santos
CONTACT
S
Samuel Yamshon, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here